Aug 22, 2026·Score 83·Type B — Growth-style analysisUsed for higher-growth companies — weighs revenue trajectory, total addressable market (TAM) expansion, and forward-looking multiples.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$39.67
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$35.00($33.00–$37.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$51.55
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type B - IDEAYA Biosciences, Inc. (IDYA) 20260822 Stock Analysis
📅 IDEAYA Key Upcoming Events
September 06, 2026IASLC 2026 World Conference on Lung Cancer Data Presentation (Confirmed)
Description: Hengrui Pharma, IDEAYA’s partner in China, will present comprehensive Phase 1 safety and efficacy data from over 70 patients for IDE849 (a DLL3 TOP1 ADC) targeting small-cell lung cancer. This marks a critical readout for the company’s antibody-drug conjugate diversification strategy.
October 2026ESMO 2026 Congress Presentations (Estimated)
Description: IDEAYA plans to present updated objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) data from the single-arm Phase 2 OptimUM-01 trial of darovasertib in HLA*A2:01-positive metastatic uveal melanoma patients.
November 03, 2026Q3 2026 Earnings Release (Estimated)
Description: The market will closely monitor the company’s research and development burn rate, sequential collaboration revenue recognition from the Servier partnership, and crucial timeline updates regarding the darovasertib New Drug Application (NDA) submission progress.
December 2026R&D Day and MTAP/CDKN2A Pipeline Update (Estimated)
Description: IDEAYA will host an R&D day in the fourth quarter to present initial clinical data from the IDE034 Phase 1 dose-escalation trial, update stakeholders on the IDE397/IDE892 combinations, and outline broader growth strategies in MTAP-deleted cancers.
December 2026Phase 1 Combination Trial Initiation of IDE892 and RG6505 (Estimated)
Description: IDEAYA will initiate a clinical combination trial alongside Genentech (a member of the Roche Group) to evaluate IDE892 (a PRMT5 inhibitor) with RG6505 (a pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.
🏢 Step 1: IDEAYA Company Overview & Business Model
Q1-A1. What is IDEAYA?
Company Name (Ticker): IDEAYA Biosciences, Inc. (IDYA)
Sector: Healthcare
Exchange: NASDAQ
Founded: June 2015
Listing Date: May 23, 2019
Fiscal Year End: December
Headquarters: United States, South San Francisco
CEO: Yujiro S. Hata
Market Cap: $3.77B
Shares Outstanding: 96.49M
Current Price:$39.67
Annual Dividend Yield: ➖ Not applicable
Ex-dividend Date: ➖ Not applicable
As-of: August 22, 2026 (ET)
Q1-A2. How Does IDEAYA Make Money?
Business Model and Value Generation: IDEAYA Biosciences operates as a clinical-stage precision medicine oncology company. The company does not currently generate revenue from commercial product sales. Instead, it drives value by discovering and developing targeted therapeutics for patient populations selected via molecular diagnostics, specifically focusing on synthetic lethality, metabolic dependencies, and epigenetic alterations.
Monetization through Strategic Partnerships: The company’s immediate monetization strategy relies on securing massive upfront capital and milestone payments by out-licensing the global or regional commercial rights of its late-stage assets. A prime example is the August 2025 exclusive license agreement with Servier for darovasertib outside the United States, which delivered a $210.0 million upfront payment alongside up to $320.0 million in potential milestones and tiered royalties. This framework allows IDEAYA to fund its resource-intensive United States clinical trials while offloading the severe capital expenditures of foreign commercial infrastructure.
Q1-A3. IDEAYA’s Revenue Segments & Core Income Sources
Collaboration Revenue (100%): Because IDEAYA is pre-commercial, its top line consists entirely of collaboration revenue derived from strategic partnerships. During the second quarter of 2026, the company reported $8.9 million in collaboration revenue, marking a steady sequential acceleration from the $6.6 million recognized in the first quarter of 2026.
Deferred Revenue Recognition: The core driver of current income is the amortization of research and development service obligations tied to the Servier agreement. As of mid-2026, IDEAYA holds a remaining balance of approximately $147.0 million for R&D services under this license, which is systematically recognized over time as the company fulfills its clinical trial execution duties. This mechanism provides a highly predictable, non-dilutive capital stream to offset ongoing operational expenditures.
Q1-A4. Who Are IDEAYA’s Competitors?
Direct Competitors in Synthetic Lethality: The synthetic lethality and precision oncology space is intensely competitive. IDEAYA’s most direct rival in the MTAP-deleted arena is Tango Therapeutics (TNGX), which is also aggressively advancing PRMT5 inhibitors. Broader competition in the precision oncology ecosystem comes from established biopharmaceutical heavyweights like Amgen, which is developing AMG 193, an investigational MTA-cooperative PRMT5 inhibitor.
Disrupted Victim (Standard-of-Care Chemotherapy): The primary victims of IDEAYA’s success are traditional, broad-spectrum chemotherapies and untargeted radiation regimens. These legacy treatments are highly toxic and generally ineffective against molecularly defined tumors, making IDEAYA’s highly targeted synthetic lethal approach an existential threat to their historical standard-of-care dominance.
Strategic Position (First Mover): IDEAYA is positioning itself as a dominant first mover in distinct genetic nodes. By locking up exclusive intellectual property around MTA-cooperative PRMT5 inhibitors (IDE892) and MAT2A inhibitors (IDE397), the company has established an insurmountable head start in combination therapies specifically targeting the MTAP-deleted solid tumor population.
Q1-A5. What Problem Does IDEAYA Solve?
Exploiting Hidden Tumor Vulnerabilities: Cancer cells frequently delete critical tumor suppressor genes (such as MTAP) to bypass standard cellular regulation. However, these deletions inadvertently create extreme dependencies on secondary survival pathways. IDEAYA solves the problem of untargetable cancers by employing “synthetic lethality”—administering a highly selective small molecule that inhibits this secondary pathway. This surgically eradicates the cancer cells that rely on it while completely sparing healthy tissue that maintains redundant survival mechanisms.
Addressing Unmet Needs in Rare Indications: Metastatic uveal melanoma (mUM) is an aggressively lethal disease. While the incidence is rare—approximately 1,700 cases diagnosed annually in the United States—almost all patients die within one year upon metastasis. Historical treatments offer minimal progression-free survival. IDEAYA solves this profound unmet medical need with the darovasertib and crizotinib combination, which has demonstrated a remarkable halving of disease progression risk compared to investigator’s choice therapies.
Q1-A6. IDEAYA Key Milestones: Past 12 Months
December 09, 2025GSK Formally Terminates Collaboration on Two Clinical Programs
Description: GlaxoSmithKline issued written notice terminating its 2020 partnership regarding the Werner Helicase (IDE275) and Pol Theta (IDE705) programs. IDEAYA subsequently evaluated its strategic options and chose to discontinue development of the returned assets to concentrate capital on its primary portfolio.
February 17, 2026Mutual Wind-Down of the Amgen IDE397 and AMG 193 Trial
Description: IDEAYA and Amgen mutually agreed to terminate their combination study. IDEAYA strategically pivoted to focus entirely on its wholly-owned, proprietary combination of IDE397 and IDE892 in MTAP-deleted non-small cell lung cancer, consolidating future commercial economics.
June 10, 2026Closing of a Massive $323.4 Million Public Equity Offering
Description: Capitalizing on strong clinical data, the company successfully fortified its balance sheet by closing an underwritten public offering of 7.22 million common shares and 5.55 million pre-funded warrants, pushing total liquidity past $1.24 billion to fully fund operations into 2030.
July 27, 2026Initiation of Part 2 Monotherapy Expansion for IDE892
Description: The company advanced its potential best-in-class MTA-cooperative PRMT5 inhibitor into monotherapy expansion in MTAP-deleted non-small cell lung cancer and pancreatic cancer. Crucially, this was achieved at projected efficacious human exposures without reaching a maximum tolerated dose.
August 04, 2026Q2 2026 Earnings Release
Description: The company announced that the registrational Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib met its primary endpoint in first-line HLA*A2:01-negative metastatic uveal melanoma. The combination delivered a statistically significant improvement in median progression-free survival to 6.9 months versus 3.1 months for legacy treatments.
August 19, 2026Clinical Collaboration Established with Genentech in Pancreatic Cancer
Description: IDEAYA secured a strategic partnership with Genentech (a Roche Group member) to evaluate IDE892 in combination with Genentech’s KRAS G12D inhibitor GDC-7035, specifically targeting the devastating genetic co-alterations of MTAP and KRAS in pancreatic ductal adenocarcinoma.
Q1-A7. Step 1 Key Takeaways
Step 1 Summary: IDEAYA is successfully executing an elite precision oncology strategy, leveraging an unparalleled synthetic lethality platform and an impregnable $1.24 billion balance sheet to advance highly de-risked assets toward commercialization without the existential dilution threat typical of its peers.
Top 3 Red Flags:
1 The immediate fundamental thesis relies entirely on the FDA accepting and approving the darovasertib New Drug Application (NDA) under the Real-Time Oncology Review (RTOR) program without requiring mature overall survival data.
2 Operating expenses are experiencing rapid hyper-inflation; total R&D expenditures surged to $108.7 million in Q2 2026 alone, highlighting the staggering cost of concurrent global oncology trials.
3 Clinical trial risk remains severe in the company’s early-stage assets, particularly concerning potential overlapping toxicities when combining PRMT5 and MAT2A inhibitors.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 Timeline updates and regulatory feedback regarding the darovasertib NDA submission target in the second half of 2026.
2 The trajectory of the quarterly cash burn rate against the $1.24 billion liquidity reserve.
3 Efficacy and objective response rates (ORR) emerging from the IDE892 and IDE397 Phase 1/2 monotherapy and combination expansion cohorts.
4 The recognition schedule of the remaining $147.0 million in Servier collaboration R&D obligations.
5 Clinical progression of the IDE849 (DLL3 TOP1 ADC) program licensed from Hengrui Pharma, which acts as a crucial modality diversifier.
Top 3 Unconfirmed and Estimated:
1 The exact timing of a potential commercial launch for darovasertib and the scope of its initial FDA labeling restrictions.
2 The ultimate overall survival (OS) data from the OptimUM-02 trial, which currently remains immature and is slated for an interim analysis in mid-2027.
3 Whether the IDE034 (B7H3/PTK7 bispecific TOP1 ADC) will demonstrate an acceptable safety profile in its ongoing Phase 1 dose escalation trial slated for initial data by late 2026 or early 2027.
Technology and Data Monopoly: IDEAYA’s moat is entrenched in deep translational biology and proprietary molecular diagnostics. The company holds exclusive patents and vast preclinical data libraries surrounding its MTA-cooperative PRMT5 inhibitor (IDE892) and MAT2A inhibitor (IDE397). Competitors face immense, capital-intensive hurdles attempting to engineer molecules that match IDE892’s 1,400-fold target selectivity. This extreme precision prevents catastrophic off-target toxicity, functionally locking out inferior competing molecules.
Network Effects and Scalability: ➖ Not applicable: Pharmaceutical developers rely on clinical superiority and regulatory approval rather than user-based network effects to establish market dominance.
Switching Costs: In the context of life-or-death oncology, switching costs are practically absolute. Once an oncologist successfully stabilizes a metastatic uveal melanoma patient on the darovasertib combination with a manageable side-effect profile, they will virtually never transition the patient to an unproven competitor due to the horrific mortality risks inherent in the disease.
Strong fandom and satisfaction (NPS): ➖ Not applicable: As the company remains strictly pre-commercial, traditional net promoter scores cannot be evaluated.
Future pricing power outlook: The pricing power embedded in IDEAYA’s pipeline is monumental. Because darovasertib targets an orphan indication (mUM) with no effective standard-of-care alternatives, IDEAYA will operate in an inelastic demand environment. This grants the company massive leverage to dictate premium biologic pricing upon FDA approval without facing severe pushback from pharmacy benefit managers or national health systems.
Q2-A2. How Big Is IDEAYA’s Market? (TAM)
TAM (Total Market): The initial beachhead market, metastatic uveal melanoma, is highly concentrated with approximately 1,700 new diagnoses annually in the United States and roughly 5.6 cases per million globally. However, this is merely a proof-of-concept. IDEAYA’s true TAM lies in its broader synthetic lethality pipeline targeting MTAP-deleted cancers. MTAP deletions occur in approximately 15% of all human solid tumors, including massive indications like non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma.
CAGR (Market Growth Rate): The precision oncology and genetic testing sector is experiencing rapid expansion, generally exhibiting a double-digit CAGR exceeding 10% as next-generation sequencing becomes the standard of care in major global cancer centers.
Upside Potential: The revenue potential is staggering relative to the current valuation. Wall Street analysts estimate that peak sales for the MAT2A inhibitor alone could reach $1.2 billion in MTAP-deleted cancers. When factoring in darovasertib and IDE892, the theoretical peak sales capacity is a significant multiple of the company’s current $3.77 billion market capitalization.
Q2-A3. How Real Is IDEAYA’s TAM? (Quality Check)
Willingness to Pay (WTP): The oncology sector commands the highest willingness to pay within the entire healthcare ecosystem. Global health insurers and private payers routinely authorize hundreds of thousands of dollars annually for targeted therapies that can significantly double progression-free survival—a clinical milestone that darovasertib has already achieved in its registrational Phase 2/3 trial.
Market Structure: The precision oncology market operates as a series of fragmented genetic monopolies. Rather than fighting broad, cutthroat battles against legacy chemotherapy, IDEAYA’s targeted approach allows it to establish absolute “winner-takes-all” dominance within specific genetic subsets, such as MTAP-deleted or HLA*A2:01-negative patient populations.
Regulation/Entry Barriers: The barriers to entry are practically insurmountable for undercapitalized players. Securing FDA approval demands hundreds of millions of dollars, years of rigorous Phase 1-3 clinical execution, and highly specialized translational biology expertise. IDEAYA’s advanced trial status and vast liquidity insulate it heavily from disruptive new entrants.
Q2-A4. Can IDEAYA Keep Expanding Its Market?
Penetration rate: ➖ Not applicable: IDEAYA remains entirely in the pre-commercial clinical phase with 0% current commercial market penetration.
Structural Scalability: The structural scalability of the business is exemplary. IDEAYA has successfully de-risked global distribution by out-licensing ex-US commercial rights to Servier. This ensures that darovasertib can reach European and Asian markets seamlessly without requiring IDEAYA to incur the crushing overhead of building international sales and regulatory infrastructure.
Zero Marginal Cost: While physical drug manufacturing inherently carries proportional costs, the gross margins for proprietary small-molecule precision oncology drugs regularly exceed 90%. Once the fixed R&D and trial costs are sunk, every incremental prescription generates explosive, highly scalable profitability.
Q2-A5. Step 2 Key Takeaways
Scoring Rationale:
Economic Moat (9/10): Unparalleled intellectual property, 1,400-fold target selectivity, and deep translational biomarker expertise forge an exceptionally durable scientific moat against competitors.
Market Size (5/5): By targeting the MTAP deletion present in 15% of all solid tumors, the company unlocks a massive, multi-billion-dollar global addressable market.
Market Quality·Profitability (6/7): The oncology market guarantees inelastic demand and supreme pricing power, though intense regulatory scrutiny tempers perfect execution.
Market Penetration·Scalability (8/8): The Servier partnership secures frictionless, capital-efficient global scalability for the lead asset while retaining the highly lucrative US rights.
Step 2 Summary: Protected by an elite, scientifically validated economic moat, IDEAYA targets a profoundly lucrative precision oncology market with massive scale potential, virtually guaranteeing premium pricing power upon commercialization.
🚀 Step 3: How Fast Is IDEAYA Growing? Hyper-Growth Metrics
Q3-A1. How Fast Is IDEAYA Growing? (Revenue Trajectory)
Check J-Curve: Standard commercial J-curves do not apply to a clinical-stage biotech. However, the company’s collaboration revenue trajectory displays significant momentum. In Q2 2026, IDEAYA recognized $8.9 million in collaboration revenue, which represents a highly robust 35.0% sequential acceleration compared to the $6.6 million generated in Q1 2026.
Acceleration: The broader top-line narrative is entirely dictated by milestone execution. In FY 2025, IDEAYA recognized a staggering $218.7 million in revenue, a 3,024% year-over-year surge driven directly by the massive $210 million upfront payment from the Servier darovasertib licensing deal. While this creates lumpy year-over-year comparisons, the rapid amortization of the remaining $147.0 million in R&D service obligations confirms steady, accelerating baseline revenue generation.
Q3-A2. IDEAYA’s Key Growth Metrics
Biotech/Drug Platforms: Clinical stage progress in the pipeline, the cumulative value of technology transfer agreements, and the ability to address unmet needs in target markets are chosen as the definitive growth metrics because IDEAYA drives enterprise value through FDA trial execution and partnership validation rather than recurring consumer subscriptions.
Clinical Pipeline Acceleration: The velocity of clinical execution is peerless. IDEAYA definitively shattered the efficacy barrier in its Phase 2/3 OptimUM-02 trial, delivering a median progression-free survival (PFS) of 6.9 months versus 3.1 months for legacy therapies, backed by a dominant hazard ratio of 0.42 (p<0.0001). Simultaneously, IDE397 established a 39% overall response rate in Phase 2 trials, and IDE892 rapidly advanced into Part 2 monotherapy expansion, proving the platform’s multi-asset viability.
Q3-A3. Are IDEAYA’s Unit Economics Improving?
➖ Not applicable: The company has no approved products on the market. Therefore, standard unit economics such as gross margin expansion, the Rule of 40, and LTV/CAC ratios are mathematically impossible to calculate and structurally irrelevant at this stage of the corporate lifecycle.
Q3-A4. Step 3 Key Takeaways
Scoring Rationale:
Revenue Growth Acceleration (9/12): Collaboration revenue exhibits highly predictable sequential quarterly growth driven by R&D service amortization, heavily backstopped by massive, transformational upfront milestone events.
Sector-Specific Growth Metrics (10/10): Pipeline execution is flawless; delivering a 0.42 hazard ratio in a registrational Phase 2/3 oncology trial is the ultimate validation of explosive fundamental growth.
Unit Economics·Margin (4/8): A neutral score is applied because traditional unit economics cannot be evaluated, though the margin profile of future targeted oncology sales is implicitly highly favorable.
Step 3 Summary: IDEAYA is perfectly executing the hyper-growth playbook required of elite biotechs, rapidly propelling multiple highly disruptive assets through late-stage trials while securing massive non-dilutive capital through strategic out-licensing.
Margin Trajectory: IDEAYA’s operating losses are intentionally expanding at a rapid pace. For Q2 2026, the company reported a massive net loss of $112.5 million, marking a 14.1% sequential widening from the $98.5 million loss in Q1 2026. This deficit is fueled entirely by a surge in research and development expenses, which hit $108.7 million for the quarter as the company funds expensive, multi-cohort global clinical trials.
Entering the Profit and Margin Expansion (BEP & Margin Expansion): The path to profitability is absolutely binary and contingent on commercialization. The company will not achieve operational break-even within the next 1-2 years. The aggressive cash burn is a deliberate strategic choice to rapidly fund the darovasertib NDA submission and scale the IDE397/IDE892 combinations, exchanging near-term deficits for future monopoly pricing power.
Q4-A2. Does IDEAYA Generate Free Cash Flow?
FCF Generation Power: The company generates heavily negative free cash flow, posting a trailing twelve-month FCF of -$113.87 million. The capital intensity required to manufacture trial supplies and fund clinical enrollment across multiple global sites ensures that free cash flow will remain deeply negative until product commercialization or massive new milestone triggers occur.
Self-Funding: Despite the intense cash burn, IDEAYA exhibits extraordinary capital security. Management successfully executed a $323.4 million underwritten public offering in June 2026, pushing the company’s total cash, cash equivalents, and marketable securities to a staggering $1.24 billion. This fortress balance sheet entirely self-funds the aggressive development pipeline, providing an uninterrupted operational runway well into 2030 without any reliance on toxic debt financing.
Q4-A3. Step 4 Key Takeaways
Scoring Rationale:
Operating Leverage·Path to Profit (6/8): While deeply unprofitable, the widening losses represent highly efficient capital deployment into late-stage trials that directly multiply future enterprise value.
FCF·Capital Efficiency (8/7) ➡ capped 7/7: The astronomical $1.24 billion cash reserve perfectly insulates the company from capital markets risk, securing a pristine operational runway through the end of the decade.
Step 4 Summary: Although intrinsically loss-making and cash-burning, IDEAYA wields one of the strongest balance sheets in the mid-cap biotech sector, affording immense capital efficiency and entirely de-risking its clinical runway.
Founder-Led: IDEAYA benefits from elite founder-led continuity. Yujiro S. Hata, the founder, President, and Chief Executive Officer, continues to steer the strategic direction of the company, avoiding the disruptive executive turnover that frequently plagues clinical-stage biotechs.
Vision: Hata and his executive team operate with a ruthless, highly focused mission: to dominate the emerging field of synthetic lethality. By recruiting top-tier talent, such as Chief Scientific Officer Dr. Michael White—formerly the Head of Tumor Biology at Pfizer and an acclaimed academic at UT Southwestern—management has cemented IDEAYA as the undisputed scientific leader in precision targeted therapeutics.
Guidance Hit Rate: Management’s track record of executing clinical and regulatory timelines is immaculate. The company consistently delivers data readouts, trial enrollment targets, and partnership milestones squarely within the precise quarterly windows promised to Wall Street.
Transparency and Consistency: The leadership team is highly transparent, refusing to obfuscate setbacks. When GSK unexpectedly terminated its collaboration on two programs, and when IDEAYA mutually agreed with Amgen to wind down a high-profile combination trial, management immediately disclosed the events and provided clear, strategic rationales without defensive posturing.
Q5-A2. Is IDEAYA’s Management Aligned With Shareholders?
Skin in the Game: Executive leadership retains significant equity exposure, aligning their personal wealth directly with the long-term appreciation of the stock. Executives are routinely granted massive tranches of non-qualified stock options under aggressive four-year vesting schedules, ensuring they must deliver sustained commercial success to unlock value.
Insider trading (words and actions match): Recent insider activity reveals highly encouraging institutional conviction. Independent Director Jeffrey Stein purchased 50,000 shares in the open market for approximately $1.6 million. While Chief Accounting Officer Andres Ruiz Briseno sold 9,550 shares for roughly $382,130 in July 2026, the filing explicitly confirmed this was a programmatic exercise under a pre-established Rule 10b5-1 trading plan adopted months prior, completely dispelling any notion of opportunistic “fleeing” by management.
Compensation system: The compensation architecture relies intensely on long-term equity inducement grants. By tethering the bulk of executive rewards to future stock performance rather than massive base salaries, the board enforces strict alignment with long-term shareholder value enhancement.
Q5-A3. Step 5 Key Takeaways
Scoring Rationale:
Founder Management·Vision (8/8): The founder-led executive team, bolstered by elite scientific recruitment, executes complex clinical strategies with ruthless precision and unmatched transparency.
Step 5 Summary: Driven by an exceptional founder-led team and validated by robust institutional insider buying, IDEAYA maintains impeccable operational transparency and profound alignment with shareholder interests.
⛵ Step 6: IDEAYA Market Flow & Sentiment
Q6-A1. Analyst Consensus vs IDEAYA Guidance
Priced for Perfection: IDEAYA’s stock price trades heavily on future commercial expectations rather than trailing metrics. In Q2 2026, the company posted a net loss of $1.22 per share against an analyst consensus estimate of a $1.05 loss. However, the market largely ignored the wider deficit, understanding that the escalating R&D spend was directly funding the highly successful OptimUM-02 trial. Meanwhile, the company crushed revenue estimates, delivering $8.86 million against a $7.45 million expectation.
Estimate Revisions: Sell-side analysts are aggressively revising their models upward to reflect the impending darovasertib commercialization. Within the past few months, consensus revenue forecasts for 2026 were hiked by 15% (from $34.1 million to $39.4 million), while 2027 forecasts project a staggering 193% revenue surge to $115.49 million, confirming supreme market confidence in the company’s trajectory.
Q6-A2. What Is IDEAYA’s Short Interest?
Institutional Trends: IDEAYA is structurally fortified by institutional smart money, boasting an overwhelmingly dominant 98.31% institutional ownership rate. Heavyweights like Morgan Stanley, Geode Capital, and Dimensional Fund Advisors actively increased their massive positions in the latest quarter, heavily buffering the stock against erratic retail volatility and panic selling.
Short Selling Indicators: The short profile presents a fascinating, moderately constrained dynamic. Short interest sits at 9.92% of outstanding shares (approximately 9.57 million shares), carrying a Days-to-Cover ratio of 6.71. Because the vast majority of the float is tightly locked up by diamond-handed institutions, this elevated days-to-cover metric leaves short sellers highly vulnerable to a violent squeeze if the FDA accepts the NDA ahead of schedule.
Q6-A3. Step 6 Key Takeaways
Scoring Rationale:
Consensus vs Guidance (3/3): Analysts heavily favor the company, actively upward-revising forward revenue models and forgiving R&D-driven EPS misses due to the flawless clinical trial execution.
Supply·Short Interest (2/2): Near-total institutional lock-up combined with a healthy days-to-cover ratio creates an exceptionally stable price floor with distinct short-squeeze upside potential.
Step 6 Summary: Anchored by near-unanimous institutional ownership and increasingly bullish sell-side revisions, market sentiment surrounding IDEAYA remains rock-solid despite the escalating costs of clinical development.
🧨 Step 7: IDEAYA Catalysts & Price Triggers
Q7-A1. What Could Re-Rate IDEAYA Stock? (Next 12 Months)
Breakeven: ➖ Not applicable: As IDEAYA requires sustained capital deployment to aggressively advance its multi-cohort Phase 1/2 trials, operational breakeven is not projected or prioritized within the next 12 months.
New Products/Approvals: The absolute pinnacle catalyst is the targeted submission and subsequent FDA acceptance of the darovasertib New Drug Application (NDA) under the Real-Time Oncology Review (RTOR) program in the second half of 2026. A swift approval would fundamentally and permanently transition IDEAYA into a commercial-stage pharmaceutical entity.
Major orders: Clinical validation serves as the proxy for commercial orders. The market will violently re-rate the stock based on the upcoming presentation of objective response rate and survival data for HLA*A2-positive mUM at the ESMO Congress in October 2026, as well as the crucial Phase 1 readout for the IDE034 ADC program expected by late 2026.
Q7-A2. IDEAYA’s Estimate Revision Trend
Revenue Estimates: Analysts are relentlessly upgrading IDEAYA’s forward revenue potential. Driven by the milestone velocity of the Servier and Hengrui partnerships, the street has lifted 2026 revenue expectations to $39.4 million and forecasts exponential acceleration toward a $254.79 million top line by 2028, underscoring deep conviction in the synthetic lethality platform.
Q7-A3. Step 7 Key Takeaways
Scoring Rationale:
Catalyst Strength (3/3): An impending NDA submission for a highly de-risked oncology asset stands as the single most explosive valuation trigger in the biotech sector.
Estimated Trend (2/2): Unanimous, high-magnitude upward revisions in consensus forward revenue confirm broad structural momentum and institutional confidence.
Step 7 Summary: IDEAYA confronts a profoundly catalyst-rich 12-month horizon, anchored by a transformative NDA submission that virtually guarantees aggressive forward re-rating.
⚖️ Step 8: Is IDEAYA Fairly Valued? Valuation Analysis
Q8-A1. IDEAYA’s Key Valuation Multiples
PS Ratio: 16.3x (overvalued)
P/FCF Ratio: ➖ Not applicable
P/OCF Ratio: ➖ Not applicable
EV/Sales Ratio: 11.2x (overvalued)
EV/EBITDA Ratio: ➖ Not applicable
EV/FCF Ratio: ➖ Not applicable
Forward PE: ➖ Not applicable
PEG Ratio: -0.46x (undervalued)
Scoring Rationale: Unprofitable pre-commercial biotechs natively screen as highly overvalued on trailing sales metrics; the absolute price burden is severe relative to current, collaboration-only cash flows.
📌 (1) Axis Q8-A1 Score:-3
Q8-A2. IDEAYA vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Sales-based metrics are strictly mandated due to persistent operating deficits; the Price-to-Sales (PSR) ratio is selected to normalize baseline top-line collaboration momentum across the sector.
Calculation of peer-to-peer deviation rate: +146.9%
🧮 Calculation Formula: ((16.3 - 6.6) / 6.6) × 100
Scoring Rationale: The stock trades at a staggering premium compared to its most direct synthetic lethality peer, Tango Therapeutics (which trades at a 6.6x PSR), rendering IDEAYA drastically more expensive on a relative benchmark.
📌 (2) Axis Q8-A2 Score:-4
Q8-A3. What Is IDEAYA Worth in the Future? (Forward Valuation)
Implied Future Multiple: Valuing the current $3.77 billion market capitalization against the $254.79 million revenue consensus for 2028 yields an implied forward PSR of 14.8x. While the company’s growth is inherently explosive, this forward multiple heavily outpaces the mature mid-cap biotech sector average of 5-8x, indicating future commercial value is already largely priced into the stock.
Scoring Rationale: The Implied Future Multiple slightly exceeds reasonable industry standards, leaving a constrained safety margin to absorb clinical shocks without suffering downside volatility.
📌 (3) Axis Q8-A3 Score:-1
Q8-A3-1. What Growth Hurdle Does the Market Demand From IDEAYA? (Forward Valuation Alternative)
Scoring Rationale: ➖ Not applicable
📌 (3) Axis Q8-A3-1 Score:➖
Q8-A4. Final Valuation Adjustment
Scoring Rationale: The systemic valuation penalties mandated by the mechanical framework are drastically offset by exceptional fundamental circumstances. IDEAYA possesses an astronomical $1.24 billion cash reserve providing operational runway into 2030, utterly erasing traditional biotech dilution risk. Furthermore, the impending RTOR NDA submission for darovasertib provides massive commercial de-risking that is entirely uncaptured by standard trailing multiples, justifying a maximal upward exception.
Commentary: The mechanical valuation framework appropriately penalizes the stock for its inherently expensive trailing and peer-relative multiples. However, the aggressive final adjustment correctly acknowledges that IDEAYA’s immense balance sheet and pipeline maturity logically defy standard early-stage valuation gravity.
Step 8 Summary: While statistically expensive on an absolute and relative basis, IDEAYA’s premium valuation is largely justified by its peerless cash security and highly validated clinical pipeline.
💀 Step 9: What Are the Risks of IDEAYA? Fatal Risks & Pre-Mortem
Q9-A1. Is IDEAYA Burning Cash & Diluting Shareholders?
Cash Exhaustion: Cash exhaustion is effectively a non-issue. The company concluded Q2 2026 with an extraordinary $1.24 billion in liquidity, ensuring operations are fully funded deeply into 2030 without any requirement for immediate, desperate capital infusions.
Dilution: The company recently conducted a $323.4 million public offering in June 2026, alongside $33.1 million in at-the-market (ATM) sales. While this did execute a dilution event, it was highly opportunistic and surgical, designed to secure the ultimate strategic high ground. Management is not characterized by habitual, value-destructive dilution.
Q9-A2. Do Competition or Regulation Threaten IDEAYA?
Intensifying Competition: The synthetic lethality arena is becoming increasingly crowded. IDEAYA faces potent developmental pressure from Tango Therapeutics and Amgen (AMG 193), requiring impeccable trial execution to maintain its first-mover advantage in the PRMT5 and MAT2A nodes.
Regulatory Risk: The entire near-term thesis hinges on the FDA’s acceptance and subsequent approval of the darovasertib combo under the RTOR pathway. Any regulatory demand for additional safety cohorts or more mature overall survival (OS) data prior to approval could delay commercialization by years.
Q9-A3. IDEAYA Pre-Mortem: What Could Go Wrong?
If the stock price crashed by 70% a year later, the primary catalyst would be the FDA issuing a Complete Response Letter (CRL) for the darovasertib NDA due to immature overall survival data, compounded simultaneously by unexpected dose-limiting toxicities halting the IDE892 and IDE397 combination trials.
Q9-A4. Risk Adjustment Score
Reason for Scoring: The risk profile is extraordinarily mitigated by the vast cash runway, isolating the company’s downside strictly to routine clinical delays and minor competitive headwinds rather than existential financial ruin.
📊 Risk Adjustment Score:-2 pts
Step 9 Summary: IDEAYA operates with one of the cleanest risk profiles in the mid-cap biotech sector, shielded by massive liquidity that completely removes the specter of near-term bankruptcy.
Commentary: A highly commanding fundamental score is driven by a flawless moat architecture, relentless clinical pipeline acceleration, and a fortress balance sheet. The disciplined valuation framework levies a necessary penalty for the stock’s absolute premium, while a moderate risk deduction correctly identifies the structural safety afforded by the company’s massive cash reserves and de-risked late-stage assets.
Q10-A2. Should You Buy IDEAYA? (Recommendation)
Recommendation:Hold
Commentary: Combining a transformative synthetic lethality platform with an imminent NDA submission and unprecedented capital efficiency, IDEAYA offers a compelling long-term thesis; however, the elevated relative valuation and total reliance on a flawless FDA regulatory review suggest a patient accumulation approach rather than aggressive immediate buying.
Q10-A3. Investment Thesis in One Line
IDEAYA is a uniquely de-risked, cash-rich precision oncology leader poised to dominate the massive MTAP-deleted tumor market, though investors must remain hyper-vigilant regarding the inherently high relative valuation and strict reliance on forthcoming FDA regulatory verdicts.
Q10-A4. IDEAYA’s Price Trend & Key Drivers
Stock Price Trend Over the Past 12 Months:Upward 📈
August 04, 2026Registrational OptimUM-02 Trial Met Primary Endpoint
Description: The company reported that the darovasertib combo generated a highly statistically significant improvement in median progression-free survival (6.9 vs 3.1 months) in metastatic uveal melanoma, functionally clearing the path for an H2 2026 NDA submission. ➡ Stock Price Resilience
July 27, 2026Initiation of Phase 1/2 Monotherapy Expansion for IDE892
Description: IDEAYA successfully accelerated its potent PRMT5 inhibitor into monotherapy expansion without hitting maximum tolerated toxicities, cementing its clinical leadership against rival Tango Therapeutics. ➡ Stock Price Surge
June 10, 2026Closing of $323.4 Million Public Offering
Description: Capitalizing on strong clinical momentum, management executed a massive equity raise to lock in a cash runway into 2030, entirely neutralizing future dilution fears. ➡ Stock Price Stability
Q10-A5. Action Plan
Current Price:$39.67
Buy Zone:$35.00 ($33.00–$37.00)
(1) Calculation of Fundamental Value: Given the stock’s historical volatility around clinical readouts, the lower bound targets the pre-ASCO technical support base, establishing a firm Margin of Safety against broader market drawdowns.
(2) Momentum Premium/Discount Application: Because the company is actively approaching an NDA submission catalyst, we assign a slight momentum premium, raising the acceptable entry threshold to capture the impending rerating without chasing the $40+ resistance level.
(3) Conclusion: The suggested accumulation zone sits optimally below current trading levels, advising investors to leverage minor sector corrections to build long-term positions leading into Q4 clinical readouts.
Price Target:$51.55
Expected Return:+29.9% (vs. current price)
📍 Select target stock price calculation criteria:
Sales-based (PSR) — The company operates at a pre-commercial loss, making forward sales multiples the standard valuation framework for late-clinical biotechs.
🧮 Price Target Calculation Formula:
Based on Total/Enterprise Value Indicators (PSR, EV/EBITDA, EV/Sales, etc.): ($254.79M × 19.52) ÷ 96.49M = $51.55
Basis for applying the multiple: 6.6x peer average — 19.52x applied multiple — Massive growth premium applied due to the exceptionally de-risked nature of the imminent darovasertib NDA submission and a $1.24 billion cash reserve that entirely strips out clinical survival risk.
Conditions and timing for reaching price target: Achievement relies directly on the FDA’s formal acceptance of the darovasertib NDA under the RTOR pathway by the end of 2026, alongside positive synergy validation from the IDE892/IDE397 combo trials early next year.
Stop Loss:$28.00 ($26.00–$30.00)
Action trigger upon catalyst achievement:
1 FDA Accepts Darovasertib NDA under RTOR
Description: Immediate validation of commercialization timeline directly reduces pipeline risk, justifying an expansion in forward multiples. 👉 Increased Holdings (Buy)
2 IDE892/IDE397 Combo Demonstrates >40% ORR in NSCLC
Description: Proving synergy in the massive lung cancer market verifies the multi-billion-dollar TAM thesis for the synthetic lethality platform. 👉 Increased Holdings (Buy)
3 Servier Exercises Ex-US Milestone Options
Description: Triggers massive non-dilutive capital inflows, further extending the cash runway and proving third-party commercial conviction. 👉 Hold
Action trigger upon risk realization:
1 FDA Demands OS Data Maturation for Approval
Description: Mechanically pushes commercial revenue recognition back to 2028, necessitating a heavy discount to the present value of the asset. 👉 Reduction in Holdings (Sell)
2 Competitor AMG 193 Demonstrates Superior Safety Profile
Description: Severe competitive threat in the PRMT5 node forces IDEAYA into a secondary market position, slashing peak sales estimates. 👉 Wait and See (Hold)
3 IDE034 Fails to Show Efficacy in Phase 1
Description: A failure of the ADC program damages the broader pipeline diversity narrative, returning sole dependency to the core MAT2A/PRMT5 franchises. 👉 Wait and See (Hold)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Target the lower bound of the buy zone ($33.00) and restrict position sizing, acknowledging that pre-commercial biotechs inherently carry binary regulatory risks.
Neutral Investors: Accumulate near the $35.00 midpoint, utilizing staggered entry points to smooth out the volatility leading up to the Q4 2026 R&D Day.
Aggressive Investors: Initiate positions immediately at current levels and scale heavily into the H2 2026 NDA submission, optimizing for the explosive upward repricing typical of first-in-class oncology approvals.
Long-Term Tenbagger Vision:
Achieving a $37.7 billion valuation requires IDEAYA to successfully commercialize darovasertib globally while cementing IDE892/IDE397 as the ubiquitous frontline standard-of-care across all MTAP-deleted solid tumors, capturing at least 25% of that TAM over the next 7 years.
Tenbagger Reverse Simulation:
Current Market Cap × 10 = $37.7 billion
Revenue scale required to justify it = $3.5 billion to $4.5 billion
Share of TAM required = 25%
Duration at current CAGR = approximately 7 years
Note: Over the past 10 years, the average time to achieve a tenbagger was 6-8 years (4-5 years for high-growth tech sectors, 8-10 years for stable-growth sectors).
🕵️♂️ Deep Dive Analysis
Q1: Is IDEAYA’s Dependence on Ex-US Commercial Partnerships Its Biggest Weakness?
Analysis: IDEAYA entirely lacks a proprietary global commercialization engine. By relying on entities like Servier for ex-US market penetration, IDEAYA inherently surrenders a significant portion of peak sales economics to foreign partners. Darovasertib’s success in Europe and Asia is entirely out of management’s hands, tethered instead to Servier’s sales force execution. However, building out global oncology commercial infrastructure is a notoriously capital-destructive endeavor for emerging biotechs, often triggering massive shareholder dilution. By securing $210 million in upfront capital and guaranteed R&D reimbursements, IDEAYA successfully insulates itself from commercial overhead risks while retaining highly lucrative US rights. The structure provides immense non-dilutive capital, protecting the company’s exceptional $1.24 billion cash runway.
Judgment:Neutral — While it permanently caps absolute global revenue potential, the partnership-centric model is a highly rational, risk-mitigating mechanism that trades overseas margin for pristine domestic capital security.
Q2: Can IDEAYA’s 16.3x P/S Multiple Be Justified by the Impending Darovasertib NDA Submission?
Analysis: A trailing price-to-sales multiple of 16.3x screens as severely overheated in traditional equity analysis, especially when compared to peers like Tango Therapeutics trading at 6.6x. Yet, in the context of late-stage clinical oncology, trailing revenues—which currently consist only of R&D service recognition from Servier—are functionally useless for determining intrinsic value. The impending NDA submission under the FDA’s RTOR pathway for darovasertib addresses metastatic uveal melanoma, an orphan market completely desperate for a standard-of-care. The Phase 2/3 OptimUM-02 trial’s 0.42 hazard ratio and 6.9-month PFS provide overwhelming clinical dominance. Therefore, the multiple is preemptively pricing in the high-probability transition from a zero-revenue developer to a highly profitable commercial monopoly within a targeted indication.
Judgment:Fairly Valued — The elevated multiple is not an anomaly; it is a mechanical and accurate reflection of the massive enterprise risk reduction achieved by clearing the Phase 3 efficacy hurdle.
Q3: How Does IDEAYA’s Clinical Execution Compare to Rival Tango Therapeutics in the MTAP-Deleted Space?
Analysis: Both IDEAYA and Tango Therapeutics operate at the bleeding edge of synthetic lethality, competing fiercely over PRMT5 inhibition in MTAP-deleted cancers. However, IDEAYA wields a distinct first-mover clinical advantage that justifies its premium valuation. IDEAYA’s IDE892 boasts a staggering 1,400-fold target selectivity and recently advanced into Part 2 monotherapy expansion without hitting dose-limiting toxicities, demonstrating a profoundly superior safety profile. Furthermore, IDEAYA possesses its wholly-owned MAT2A inhibitor (IDE397), allowing the company to run proprietary combination regimens targeting two complementary nodes of the MTAP pathway—a strategic optionality that Tango cannot replicate internally without incurring massive licensing fees.
Judgment:Positive — IDEAYA easily justifies its market premium over Tango through superior clinical maturity, impeccable safety data, and the unmatched strategic advantage of owning multiple complementary assets within the exact same genetic pathway.
Q4: What Are the Long-Term Strategic Implications of Discontinuing the Repatriated GSK Assets?
Analysis: In late 2025, GlaxoSmithKline formally terminated its involvement with the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, returning full rights to IDEAYA. While a Big Pharma exit often acts as a catastrophic signal of underlying asset weakness, IDEAYA absorbed the blow seamlessly. Rather than senselessly burning capital to artificially revive the programs, IDEAYA evaluated its options and ruthlessly discontinued their development to concentrate its $1.24 billion war chest squarely on the MAT2A, PRMT5, and darovasertib franchises. This swift discontinuation highlights elite management discipline, proving leadership will not fall into the sunk-cost fallacy.
Judgment:Positive — The optical sting of losing a major partner is entirely offset by management’s ruthless capital allocation strategy, which successfully defended the company’s liquidity from being drained by secondary assets.
Q5: Will the Genentech Collaboration Maximize the Potential of IDE892 in Pancreatic Cancer?
Analysis: Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to conventional therapies, marked by high mortality and massive unmet need. The clinical collaboration with Genentech (a Roche subsidiary) to evaluate IDE892 alongside the KRAS G12D inhibitor GDC-7035 is a masterstroke of trial design. Because MTAP-deletions frequently co-occur with KRAS mutations, this combination strikes the tumor from two independent genetic vulnerabilities simultaneously. By partnering with Roche, IDEAYA brilliantly shifts a significant portion of the financial burden of the trial while gaining access to an elite proprietary asset, maximizing the probability of cracking one of oncology’s toughest indications without diluting its own balance sheet.
Judgment:Positive — The Genentech alliance leverages external Big Pharma resources and proprietary molecules to exponentially amplify the clinical impact of IDE892 in a high-value, high-need market.
Q6: How Does the Hengrui Pharma License for IDE849 Diversify IDEAYA’s Modality Risk?
Analysis: IDEAYA is heavily concentrated in its small-molecule synthetic lethality engine. IDE849 provides critical structural diversification. As a potential first-in-class DLL3-targeting topoisomerase I (TOP1) antibody-drug conjugate (ADC) designed for small-cell lung cancer (SCLC), IDE849 introduces a completely different therapeutic modality to the pipeline. Developed under an exclusive license with Hengrui Pharma, the upcoming presentation of Phase 1 data at IASLC 2026 acts as a massive diversification catalyst. If the ADC proves safe and efficacious, it fundamentally protects the company from the inherent biological risks of relying solely on kinase inhibitors, opening an entirely new multi-billion-dollar therapeutic avenue.
Judgment:Positive — The ADC program provides vital mechanistic diversification, radically expanding the company’s TAM and protecting the broader portfolio from targeted small-molecule resistance mechanisms.
Q7: Can Darovasertib’s Neoadjuvant Data Expand Its Peak Sales Beyond the Salvage Metastatic Setting?
Analysis: The ultimate enterprise value of darovasertib lies far beyond the immediate metastatic uveal melanoma indication. IDEAYA is actively prosecuting the drug in neoadjuvant and adjuvant settings (OptimUM-10 and OptimUM-11), aiming to intervene before the ocular melanoma metastasizes to the liver. By shrinking ocular tumors prior to surgery (enucleation) or radiation (plaque brachytherapy), darovasertib demonstrates profound potential for organ preservation and vision retention. Transitioning from a metastatic salvage therapy to an early-intervention paradigm exponentially expands the eligible patient pool and the duration of therapy, drastically elevating the asset’s peak sales trajectory and embedding it as the foundational pillar of uveal melanoma care.
Judgment:Positive — Expansion into neoadjuvant settings represents a massive, highly probable commercial upside that transforms darovasertib from a niche salvage drug into a ubiquitous frontline standard-of-care.
Q8: What Are the Risks Associated with IDEAYA’s Wholly-Owned IDE397 and IDE892 Combination Strategy?
Analysis: IDEAYA and Amgen mutually agreed to terminate their combination trial involving IDE397 and AMG 193. IDEAYA pivoted to prioritize its wholly-owned combination of IDE397 and IDE892. While retaining full control over both nodes of the MTAP/PRMT5 synthetic lethal pathway allows IDEAYA to capture 100% of the commercial economics without diluting value through joint venture concessions, it also internalizes 100% of the clinical risk. Combining two potent kinase inhibitors historically carries severe risks of overlapping toxicities, specifically concerning bone marrow suppression and hepatotoxicity. If the wholly-owned combo hits a dose-limiting safety wall, IDEAYA has no external partner to share the developmental fallout.
Judgment:Neutral — Winding down the Amgen trial signals profound internal confidence in IDE892, but internalizing the entire combination strategy significantly raises the clinical stakes if unexpected safety signals emerge.
Analysis: The biotechnology graveyard is littered with promising clinical assets that were abandoned or sold at fire-sale prices due to sudden cash crunches. IDEAYA’s June 2026 equity raise, which secured $323.4 million, pushed total liquidity to $1.24 billion. This capital fortress guarantees operations into 2030, fundamentally neutralizing immediate dilution risk. The company can comfortably fund the full commercial rollout of darovasertib in the US and advance multiple Phase 1/2 combination trials without ever needing to negotiate a disadvantageous licensing deal strictly for survival. The recent ATM usage of $33.1 million was surgical, not desperate.
Judgment:Positive — The cash pile transitions IDEAYA from a vulnerable biotech developer reliant on capital markets into a structurally secure, independent pharmaceutical powerhouse capable of dictating its own timeline.
Q10: Is IDEAYA Positioned as a Prime Acquisition Target for Big Pharma Amid the Ongoing Patent Cliff?
Analysis: The global pharmaceutical industry is currently characterized by a massive patent cliff, driving intense M&A activity focused on acquiring de-risked, late-stage oncology assets. With darovasertib on the cusp of an NDA submission and a synthetic lethality platform dominating the MTAP-deleted landscape, IDEAYA presents a textbook acquisition profile. A larger entity could immediately absorb the US commercialization responsibilities for darovasertib while leveraging vast global infrastructure to accelerate the IDE397/IDE892 trials. At a $3.77 billion market cap, an acquisition premium of 50-70% remains easily digestible for top-tier players desperate for validated precision oncology revenues.
Judgment:Positive — The combination of a pristine balance sheet, a validated late-stage commercial asset, and a deep proprietary pipeline makes IDEAYA one of the most compelling takeover targets in the mid-cap biotech sector.